Department of Neurology, Atlanta Veterans Affairs Medical Center, Decatur, Georgia.
Division of Cardiology, Department of Medicine, George Washington University, Washington, DC.
J Am Soc Nephrol. 2020 Mar;31(3):637-649. doi: 10.1681/ASN.2019050543. Epub 2020 Feb 20.
Because stroke prevention is a major goal in the management of ESKD hemodialysis patients with atrial fibrillation, investigating racial/ethnic disparities in stroke among such patients is important to those who could benefit from strategies to maximize preventive measures.
We used the United States Renal Data System to identify ESKD patients who initiated hemodialysis from 2006 to 2013 and then identified those with a subsequent atrial fibrillation diagnosis and Medicare Part A/B/D. Patients were followed for 1 year for all-cause stroke, mortality, prescription medications, and cardiovascular disease procedures. The survival mediational g-formula quantified the percentage of excess strokes attributable to lower use of atrial fibrillation treatments by race/ethnicity.
The study included 56,587 ESKD hemodialysis patients with atrial fibrillation. Black, white, Hispanic, and Asian patients accounted for 19%, 69%, 8%, and 3% of the population, respectively. Compared with white patients, black, Hispanic, or Asian patients were more likely to experience stroke (13%, 15%, and 16%, respectively) but less likely to fill a warfarin prescription (10%, 17%, and 28%, respectively). Warfarin prescription was associated with decreased stroke rates. Analyses suggested that equalizing the warfarin distribution to that in the white population would prevent 7%, 10%, and 12% of excess strokes among black, Hispanic, and Asian patients, respectively. We found no racial/ethnic disparities in all-cause mortality or use of cardiovascular disease procedures.
Racial/ethnic disparities in all-cause stroke among hemodialysis patients with atrial fibrillation are partially mediated by lower use of anticoagulants among black, Hispanic, and Asian patients. The reasons for these disparities are unknown, but strategies to maximize stroke prevention in minority hemodialysis populations should be further investigated.
由于预防中风是终末期肾病血液透析伴心房颤动患者治疗的主要目标,因此,研究此类患者中风的种族/民族差异对于那些可能受益于最大限度地采取预防措施的策略的人来说非常重要。
我们使用美国肾脏数据系统(United States Renal Data System)确定了 2006 年至 2013 年间开始血液透析的终末期肾病患者,然后确定了随后诊断为心房颤动并参加了医疗保险计划 A 部分/ B 部分/ D 部分的患者。在 1 年内对所有原因的中风、死亡率、处方药物和心血管疾病程序对患者进行随访。生存中介 g 公式量化了由于种族/民族原因导致抗心律失常药物使用率较低而导致的额外中风的百分比。
本研究纳入了 56587 名患有心房颤动的终末期肾病血液透析患者。黑人、白人、西班牙裔和亚洲患者分别占总人口的 19%、69%、8%和 3%。与白人患者相比,黑人、西班牙裔或亚洲患者发生中风的风险更高(分别为 13%、15%和 16%),但服用华法林的可能性较低(分别为 10%、17%和 28%)。华法林的使用与中风率降低相关。分析表明,将华法林的分布调整至白人人群的水平,可以分别预防黑人、西班牙裔和亚洲患者中 7%、10%和 12%的额外中风。我们未发现种族/民族差异与全因死亡率或心血管疾病程序的使用有关。
在患有心房颤动的血液透析患者中,全因中风的种族/民族差异部分是由于黑人、西班牙裔和亚洲患者抗凝剂使用率较低导致的。这些差异的原因尚不清楚,但应进一步研究最大限度地预防少数族裔血液透析人群中风的策略。